Frédéric Le Gal

Safety and efficacy of REP 2139 and pegylated interferon alfa-2a for treatment-naive patients with chronic hepatitis B virus and hepatitis D virus co-infection (REP 301 and REP 301-LTF): a non-randomised, open-label, phase 2 trial

Michel Bazinet, Victor Pântea, Valentin Cebotarescu et al. · ˜The œLancet. Gastroenterology & hepatology · 2017 · 249 citations · Full text

Pharmacy, Internal Medicine, Pharmacotherapy +11

Efficacy of peginterferon alpha-2b in chronic hepatitis delta: Relevance of quantitative RT-PCR for follow-up

Corinne Castelnau, Frédéric Le Gal, Marie–Pierre Ripault et al. · Hepatology · 2006 · 238 citations

Pharmacy, Pharmacology, Pharmacotherapy +17

Eighth Major Clade for Hepatitis Delta Virus

Frédéric Le Gal, Elyanne Gault, Marie–Pierre Ripault et al. · Emerging infectious diseases · 2006 · 206 citations · Full text

Life Sciences, Genetics, Microbiology +16

Origin, HDV genotype and persistent viremia determine outcome and treatment response in patients with chronic hepatitis delta

Dominique Roulot, Ségolène Brichler, Richard Layese et al. · Journal of Hepatology · 2020 · 154 citations

Life Sciences, Infectious Diseases, Hepatology +16

Genetic diversity and worldwide distribution of the deltavirus genus: A study of 2,152 clinical strains

Frédéric Le Gal, Ségolène Brichler, Tudor Drugan et al. · Hepatology · 2017 · 153 citations

Life Sciences, Genetics, Microbiology +17